**Sodium-glucose cotransporter 2 (SGLT2) inhibitors** are medicines initially used for diabetes, but they now help people with heart failure. Heart failure is when the heart can't pump blood well. **SGLT2 gene**, also called **SLC5A2**, makes important parts of the body that help with sugar absorption. Some people have changes in their **SLC5A2 gene** that might change how well SGLT2 inhibitors work for them. This study looks at how these genetic changes affect the medicine's success in heart failure patients.
**Key Points:**
- Participants will be heart failure patients classified as NYHA class II or III. They will continue with their SGLT2 treatment.
- Participants must be able to sign informed consent and should not have recent heart surgeries or severe kidney issues.
- Pregnant or breastfeeding women cannot join.
If you join, you'll help doctors understand how genetic differences affect the use of SGLT2 inhibitors, possibly improving future treatments for heart failure.
How understandable was the trial content above?
Hard to understand
Easy to understand